ADVERTISEMENT

Spain

Almirall CEO Sounds Alarm Over Europe’s Reduced Competitiveness

The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.

Almirall Looks To Dominate Across Derma Spectrum

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Barcelona Health Hub: Where Digital Health Innovation Meets Historic Art Nouveau

The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.

Spain Boosts Transparency On Reimbursement Decisions And Sheds Light On Agreements With Companies

The first reimbursement reports published by the Spanish health ministry to improve transparency focus on CSL’s Hemgenix, BMS’ Camzyos and Pfizer’s Velsipity.

Barcelona Health Hub: Where Digital Health Innovation Meets Historic Art Nouveau

In this first of a two-part series highlighting digital and healthtech innovation in Barcelona, Medtech Insight visits the Barcelona Health Hub, a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.

Almirall Predicts Plenty More Growth In Psoriasis

The Spanish group has upped its peak sales guidance for Ilumetri to €300m and believes the arrival of Stelara biosimilars will take a while to have much of an impact on the originator IL-23 class.

Neuraxpharm Strikes Long-Acting Injectables Deal With Pharmathen

The two companies have signed a co-development agreement focused on the potential creation of new long-acting injectable therapies for psychiatric conditions for an undisclosed financial sum.

Gene Therapy Hemgenix Gains Ground In Europe With Spanish Reimbursement Deal

Hemgenix has now secured reimbursement in several European markets, with more talks ongoing. While the path to reimbursement has not always been easy, innovative access deals have helped to smooth the way.

Spain Consults On HTA Regulations

New rules on health technology assessments in Spain make room for real-world evidence and early dialog.